What it's for (Indications)
- Valsartan + Amlodipine + Hydrochlorothiazide is indicated for the treatment of hypertension (high blood pressure) in patients whose blood pressure is not adequately controlled with dual therapy or as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals.
- This triple combination therapy is designed to provide comprehensive blood pressure reduction through multiple complementary mechanisms, offering a potent approach for individuals requiring significant and sustained control of their elevated blood pressure.
- Its use should be individualized based on patient response and clinical status, aiming to reduce the risk of cardiovascular events associated with uncontrolled hypertension.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of valsartan + amlodipine + hydrochlorothiazide is provided as fixed-dose combination tablets for once-daily oral administration. Available strengths typically include various combinations of valsartan (e.g., 160 mg, 320 mg), amlodipine (e.g., 5 mg, 10 mg), and hydrochlorothiazide (e.g., 12.5 mg, 25 mg). The specific strength prescribed should be individualized based on the patient's existing antihypertensive regimen, blood pressure response, and tolerability to the individual components. It is generally recommended to use the lowest effective dose for each component. Dosage adjustments should be made gradually, typically after 2-4 weeks, to assess full therapeutic effect. The medication can be taken with or without food. The maximum recommended dose should not be exceeded. |
Safety & Warnings
Common Side Effects
- Common side effects associated with valsartan + amlodipine + hydrochlorothiazide may include dizziness, headache, peripheral edema (swelling of ankles/feet), nasopharyngitis, fatigue, and nausea.
- Less common but notable side effects can involve orthostatic hypotension, palpitation, cough, muscle spasms, diarrhea, and abdominal pain.
- Due to the diuretic component (hydrochlorothiazide), electrolyte disturbances such as hypokalemia, hyponatremia, and hypomagnesemia may occur.
- Furthermore, elevation of uric acid and glucose levels has been observed.
- Amlodipine can sometimes lead to flushing and gingival hyperplasia.
- Patients should be advised to report any persistent or severe side effects to their healthcare provider for evaluation and potential management.
Serious Warnings
- Black Box Warning: **WARNING: FETAL TOXICITY** Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, valsartan + amlodipine + hydrochlorothiazide should be discontinued as soon as possible. There have been reports of fetal injury, including oligohydramnios, fetal lung hypoplasia, skeletal deformations, and death, when angiotensin receptor blockers (ARBs) were used during the second and third trimesters of pregnancy. The use of valsartan during the second and third trimesters is particularly associated with significant fetal renal dysfunction and adverse outcomes. Therefore, women of childbearing potential should be informed of the potential risks if they become pregnant while taking this medication. If pregnancy occurs, alternative antihypertensive therapies with a more favorable fetal safety profile should be considered and promptly initiated.
- This medication carries several important warnings.
- It may cause symptomatic hypotension, especially in volume-depleted patients or those receiving high doses of diuretics, necessitating careful monitoring of blood pressure.
- The valsartan component can lead to hyperkalemia, while hydrochlorothiazide can induce hypokalemia, requiring electrolyte surveillance.
- Acute transient myopia and acute angle-closure glaucoma have been reported with hydrochlorothiazide, requiring immediate discontinuation if symptoms occur.
- Worsening of renal function, particularly in patients with renal artery stenosis, is a concern due to the ARB component.
- Angioedema, a potentially life-threatening hypersensitivity reaction, has been reported with ARBs.
- Thiazide diuretics may exacerbate or activate systemic lupus erythematosus and can affect glucose metabolism, necessitating caution in diabetic patients.
- Caution is also advised in patients with severe aortic stenosis or hypertrophic obstructive cardiomyopathy, as amlodipine may worsen these conditions.
How it Works (Mechanism of Action)
Valsartan + Amlodipine + Hydrochlorothiazide is a combination antihypertensive therapy comprised of three distinct agents with complementary mechanisms of action to effectively lower blood pressure. Valsartan, an angiotensin II receptor blocker (ARB), selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction, aldosterone secretion, and other cellular effects of angiotensin II, leading to vasodilation and reduced peripheral vascular resistance. Amlodipine, a dihydropyridine calcium channel blocker, directly relaxes vascular smooth muscle by inhibiting the transmembrane influx of calcium ions, resulting in peripheral arterial vasodilation and a reduction in afterload. Hydrochlorothiazide, a thiazide diuretic, increases the excretion of sodium, chloride, and water by inhibiting sodium reabsorption in the distal convoluted tubules, which reduces plasma volume and cardiac output, initially. Long-term effects involve a reduction in peripheral vascular resistance. The synergistic action of these three components provides robust and sustained blood pressure control.
Commercial Brands (Alternatives)
No other brands found for this formula.